{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T23:52:12Z","timestamp":1788825132989,"version":"build-2803163510"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":467,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T00:00:00Z","timestamp":1720137600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Arterial hypertension (aHTN) plays a fundamental role in the pathogenesis and prognosis of heart failure with preserved ejection fraction (HFpEF). The risk of heart failure increases with therapy-resistant arterial hypertension (trHTN), defined as inadequate blood pressure (BP) control \u2265140\/90 mmHg despite taking \u22653 antihypertensive medications including a diuretic. This study investigates the effects of the BP lowering baroreflex activation therapy (BAT) on cardiac function and morphology in patients with trHTN with and without HFpEF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Sixty-four consecutive patients who had been diagnosed with trHTN and received BAT implantation between 2012 and 2016 were prospectively observed. Office BP, electrocardiographic and echocardiographic data were collected before and after BAT implantation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Mean patients' age was 59.1 years, 46.9% were male, and mean body mass index (BMI) was 33.2 kg\/m2. The prevalence of diabetes mellitus was 38.8%, atrial fibrillation was 12.2%, and chronic kidney disease (CKD) stage \u22653 was 40.8%. Twenty-eight patients had trHTN with HFpEF, and 21 patients had trHTN without HFpEF. Patients with HFpEF were significantly older (64.7 vs. 51.6 years, P &amp;lt; 0.0001), had a lower BMI (30.0 vs. 37.2 kg\/m2, P &amp;lt; 0.0001), and suffered more often from CKD-stage \u22653 (64 vs. 20%, P = 0.0032). After BAT implantation, mean office BP dropped in patients with and without HFpEF (from 169 \u00b1 5\/86 \u00b1 4 to 143 \u00b1 4\/77 \u00b1 3 mmHg [P = 0.0019 for systolic BP and 0.0403 for diastolic BP] and from 170 \u00b1 5\/95 \u00b1 4 to 149 \u00b1 6\/88 \u00b1 5 mmHg [P = 0.0019 for systolic BP and 0.0763 for diastolic BP]), while a significant reduction of the intake of calcium-antagonists, \u03b12-agonists and direct vasodilators, as well as a decrease in average dosage of ACE-inhibitors and \u03b12-agonists could be seen. Within the study population, a decrease in heart rate from 74 \u00b1 2 to 67 \u00b1 2 min\u22121 (P = 0.0062) and lengthening of QRS-time from 96 \u00b1 3 to 106 \u00b1 4 ms (P = 0.0027) and QTc-duration from 422 \u00b1 5 to 432 \u00b1 5 ms (P = 0.0184) were detectable. The PQ duration was virtually unchanged. In patients without HF, no significant changes of echocardiographic parameters could be seen. In patients with HFpEF, posterior wall diameter decreased significantly from 14.0 \u00b1 0.5 to 12.7 \u00b1 0.3 mm (P = 0.0125), left ventricular mass (LVM) declined from 278.1 \u00b1 15.8 to 243.9 \u00b1 13.4 g (P = 0.0203), and e\u2032 lateral increased from 8.2 \u00b1 0.4 to 9.0 \u00b1 0.4 cm\/s (P = 0.0471).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>BAT reduced systolic and diastolic BP and was associated with morphological and functional improvement of HFpEF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.14940","type":"journal-article","created":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T02:59:05Z","timestamp":1720234745000},"page":"3360-3367","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Effects of Baroreflex Activation Therapy on Cardiac Function and Morphology"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2676-9670","authenticated-orcid":false,"given":"Ann-Kathrin C.","family":"Sch\u00e4fer","sequence":"first","affiliation":[{"name":"Department of Nephrology and Rheumatology, University Medical Centre , G\u00f6ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Wallbach","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Rheumatology, University Medical Centre , G\u00f6ttingen ,","place":["Germany"]},{"name":"German Center for Cardiovascular Research (DZHK), Partner Site , G\u00f6ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Schroer","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Rheumatology, University Medical Centre , G\u00f6ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca-Yves","family":"Lehnig","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Rheumatology, University Medical Centre , G\u00f6ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"L\u00fcders","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Rheumatology, University Medical Centre , G\u00f6ttingen ,","place":["Germany"]},{"name":"St. Josefs Hospital , Cloppenburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Hasenfu\u00df","sequence":"additional","affiliation":[{"name":"German Center for Cardiovascular Research (DZHK), Partner Site , G\u00f6ttingen ,","place":["Germany"]},{"name":"Department of Cardiology and Pulmonology, University Medical Centre , G\u00f6ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Wachter","sequence":"additional","affiliation":[{"name":"German Center for Cardiovascular Research (DZHK), Partner Site , G\u00f6ttingen ,","place":["Germany"]},{"name":"Department of Cardiology and Pulmonology, University Medical Centre , G\u00f6ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Koziolek","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Rheumatology, University Medical Centre , G\u00f6ttingen ,","place":["Germany"]},{"name":"German Center for Cardiovascular Research (DZHK), Partner Site , G\u00f6ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,5]]},"reference":[{"key":"2026012113152572800_ehf214940-bib-0001","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.jacc.2003.07.046","article-title":"Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis","volume":"43","author":"Hogg","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"2026012113152572800_ehf214940-bib-0002","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1136\/hrt.2004.041996","article-title":"Heart failure with preserved left ventricular systolic function: A hospital cohort study","volume":"91","author":"Berry","year":"2005","journal-title":"Heart"},{"key":"2026012113152572800_ehf214940-bib-0003","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.ejheart.2007.12.010","article-title":"Heart failure with preserved ejection fraction: Clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial","volume":"10","author":"McMurray","year":"2008","journal-title":"Eur J Heart Fail"},{"key":"2026012113152572800_ehf214940-bib-0004","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s10741-018-9698-8","article-title":"The role of arterial hypertension in development heart failure with preserved ejection fraction: Just a risk factor or something more?","volume":"23","author":"Tadic","year":"2018","journal-title":"Heart Fail Rev"},{"key":"2026012113152572800_ehf214940-bib-0005","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2174\/1570161115666170414120532","article-title":"Hypertension and heart failure with preserved ejection fraction: Connecting the dots","volume":"16","author":"Tsioufis","year":"2017","journal-title":"Curr Vasc Pharmacol"},{"key":"2026012113152572800_ehf214940-bib-0006","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.jacc.2007.04.064","article-title":"Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: A report from the OPTIMIZE-HF registry","volume":"50","author":"Fonarow","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"2026012113152572800_ehf214940-bib-0007","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.jash.2016.08.008","article-title":"Prevalence of treatment-resistant hypertension and important associated factors-results from the Swedish primary care cardiovascular database","volume":"10","author":"Holmqvist","year":"2016","journal-title":"J Am Soc Hypertens"},{"key":"2026012113152572800_ehf214940-bib-0008","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1111\/jch.13856","article-title":"The association of hypertension, hypertension duration, and control with incident heart failure in black and white adults","volume":"22","author":"Mefford","year":"2020","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2026012113152572800_ehf214940-bib-0009","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.113.000660","article-title":"Cardiovascular and mortality risk of apparent resistant hypertension in women with suspected myocardial ischemia: A report from the NHLBI-sponsored WISE study","volume":"3","author":"Smith","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"2026012113152572800_ehf214940-bib-0010","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.amjmed.2013.07.038","article-title":"Prevalence, predictors, and outcomes in treatment-resistant hypertension in patients with coronary disease","volume":"127","author":"Bangalore","year":"2014","journal-title":"Am J Med"},{"key":"2026012113152572800_ehf214940-bib-0011","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: Executive summary: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"2026012113152572800_ehf214940-bib-0012","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"2026012113152572800_ehf214940-bib-0013","doi-asserted-by":"publisher","first-page":"E4","DOI":"10.1093\/eurheartjsupp\/suac030","article-title":"Sympathetic activation in heart failure()","volume":"24","author":"Gronda","year":"2022","journal-title":"Eur Heart J Suppl"},{"key":"2026012113152572800_ehf214940-bib-0014","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1161\/HYPERTENSIONAHA.108.121467","article-title":"Sympathetic and baroreflex cardiovascular control in hypertension-related left ventricular dysfunction","volume":"53","author":"Grassi","year":"2009","journal-title":"Hypertension"},{"key":"2026012113152572800_ehf214940-bib-0015","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1093\/ajh\/hpt032","article-title":"High muscle sympathetic nerve activity is associated with left ventricular dysfunction in treated hypertensive patients","volume":"26","author":"de Souza","year":"2013","journal-title":"Am J Hypertens"},{"key":"2026012113152572800_ehf214940-bib-0016","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.ijcard.2005.06.041","article-title":"Autonomic cardiovascular control and diastolic dysfunction in hypertensive subjects","volume":"110","author":"Piccirillo","year":"2006","journal-title":"Int J Cardiol"},{"key":"2026012113152572800_ehf214940-bib-0017","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1046\/j.1365-201X.2003.01087.x","article-title":"Sympathetic activation in human heart failure: Diverse mechanisms, therapeutic opportunities","volume":"177","author":"Floras","year":"2003","journal-title":"Acta Physiol Scand"},{"key":"2026012113152572800_ehf214940-bib-0018","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.jacc.2009.03.061","article-title":"Sympathetic nervous system activation in human heart failure: Clinical implications of an updated model","volume":"54","author":"Floras","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2026012113152572800_ehf214940-bib-0019","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s12265-014-9546-8","article-title":"The baroreceptor as a therapeutic target for heart failure","volume":"7","author":"Gronda","year":"2014","journal-title":"J Cardiovasc Transl Res"},{"key":"2026012113152572800_ehf214940-bib-0020","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/0735-1097(95)00332-0","article-title":"Adverse consequences of high sympathetic nervous activity in the failing human heart","volume":"26","author":"Kaye","year":"1995","journal-title":"J Am Coll Cardiol"},{"key":"2026012113152572800_ehf214940-bib-0021","article-title":"Arterial baroreceptors in the management of systemic hypertension","volume":"16","author":"Kougias","year":"2010","journal-title":"Med Sci Monit"},{"key":"2026012113152572800_ehf214940-bib-0022","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.jacc.2011.06.008","article-title":"Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: Results from the double-blind, randomized, placebo-controlled rheos pivotal trial","volume":"58","author":"Bisognano","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2026012113152572800_ehf214940-bib-0023","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1016\/j.jacc.2010.03.089","article-title":"Novel baroreflex activation therapy in resistant hypertension: Results of a European multi-center feasibility study","volume":"56","author":"Scheffers","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2026012113152572800_ehf214940-bib-0024","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1161\/HYPERTENSIONAHA.115.06717","article-title":"Effects of baroreflex activation therapy on ambulatory blood pressure in patients with resistant hypertension","volume":"67","author":"Wallbach","year":"2016","journal-title":"Hypertension"},{"key":"2026012113152572800_ehf214940-bib-0025","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/HJH.0000000000000361","article-title":"Effects of baroreflex activation therapy on arterial stiffness and central hemodynamics in patients with resistant hypertension","volume":"33","author":"Wallbach","year":"2015","journal-title":"J Hypertens"},{"key":"2026012113152572800_ehf214940-bib-0026","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.jchf.2015.02.006","article-title":"Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction","volume":"3","author":"Abraham","year":"2015","journal-title":"JACC Heart Fail"},{"key":"2026012113152572800_ehf214940-bib-0027","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jacc.2020.05.015","article-title":"Baroreflex activation therapy in patients with heart failure with reduced ejection fraction","volume":"76","author":"Zile","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026012113152572800_ehf214940-bib-0028","doi-asserted-by":"publisher","first-page":"E12","DOI":"10.1093\/eurheartjsupp\/suac036","article-title":"Neuromodulation devices for heart failure()","volume":"24","author":"Dusi","year":"2022","journal-title":"Eur Heart J Suppl"},{"key":"2026012113152572800_ehf214940-bib-0029","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s00392-010-0249-0","article-title":"Baroreflex activation as a novel therapeutic strategy for diastolic heart failure","volume":"100","author":"Brandt","year":"2011","journal-title":"Clin Res Cardiol"},{"key":"2026012113152572800_ehf214940-bib-0030","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.artres.2011.10.068","article-title":"Effect of carotid baroreceptor activation on ventricular function and central arterial hemodynamics: A case report based on invasive pressure-volume loop analysis","volume":"5","author":"Segers","year":"2011","journal-title":"Artery Res"},{"key":"2026012113152572800_ehf214940-bib-0031","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1097\/HJH.0b013e328364ca4c","article-title":"2013 practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH\/ESC task force for the management of arterial hypertension","volume":"31","author":"Mancia","year":"2013","journal-title":"J Hypertens"},{"key":"2026012113152572800_ehf214940-bib-0032","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"2026012113152572800_ehf214940-bib-0033","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1097\/HJH.0000000000001339","article-title":"Blood pressure after blinded, randomized withdrawal, and resumption of baroreceptor-activating therapy","volume":"35","author":"Beige","year":"2017","journal-title":"J Hypertens"},{"key":"2026012113152572800_ehf214940-bib-0034","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s00392-019-01536-5","article-title":"Long-term effects of baroreflex activation therapy: 2-year follow-up data of the BAT neo system","volume":"109","author":"Wallbach","year":"2020","journal-title":"Clin Res Cardiol"},{"key":"2026012113152572800_ehf214940-bib-0035","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1159\/000368723","article-title":"Impact of baroreflex activation therapy on renal function\u2013A pilot study","volume":"40","author":"Wallbach","year":"2014","journal-title":"Am J Nephrol"},{"key":"2026012113152572800_ehf214940-bib-0036","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1001\/jamacardio.2022.5320","article-title":"Effect of personalized accelerated pacing on quality of life, physical activity, and atrial fibrillation in patients with preclinical and overt heart failure with preserved ejection fraction: The myPACE randomized clinical trial","volume":"8","author":"Infeld","year":"2023","journal-title":"JAMA Cardiol"},{"key":"2026012113152572800_ehf214940-bib-0037","doi-asserted-by":"publisher","first-page":"311","DOI":"10.7326\/0003-4819-147-5-200709040-00006","article-title":"Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients","volume":"147","author":"Okin","year":"2007","journal-title":"Ann Intern Med"},{"key":"2026012113152572800_ehf214940-bib-0038","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1161\/HYPERTENSIONAHA.107.095216","article-title":"Chronic baroreceptor activation enhances survival in dogs with pacing-induced heart failure","volume":"50","author":"Zucker","year":"2007","journal-title":"Hypertension"},{"key":"2026012113152572800_ehf214940-bib-0039","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1161\/CIRCHEARTFAILURE.110.955013","article-title":"Chronic electrical stimulation of the carotid sinus baroreflex improves left ventricular function and promotes reversal of ventricular remodeling in dogs with advanced heart failure","volume":"4","author":"Sabbah","year":"2011","journal-title":"Circ Heart Fail"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/11\/5\/3360\/64516091\/eschf_11_5_3360.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/11\/5\/3360\/64516091\/eschf_11_5_3360.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:17:26Z","timestamp":1769019446000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/11\/5\/3360\/8271306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,5]]},"references-count":39,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,7,5]]},"published-print":{"date-parts":[[2024,10,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.14940","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,7,5]]},"assertion":[{"value":"2023-11-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}